Forge Biologics snags $120m Series B

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, has secured $120 million in Series B financing.

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, has secured $120 million in Series B financing. RA Capital Management led the round with participation from other investors that included Perceptive Advisors, Surveyor Capital, Octagon Capital, and Marshall Wace.

Source: Press Release